首页 > 最新文献

Hellenic Journal of Cardiology最新文献

英文 中文
Comparison of continuous flow centrifugal left ventricular assist devices as a bridge to transplant strategy in a low organ donation environment: Single center experience.
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-18 DOI: 10.1016/j.hjc.2024.10.004
Michael Bonios, Dimitris Miliopoulos, Angeliki Gkouziouta, Nektarios Kogerakis, Sokratis Fragkoulis, Iakovos Armenis, Dimitrios Zarkalis, Konstantinos Ieromonachos, Antigoni Koliopoulou, Evangelos Leontiadis, Panagiota Georgiadou, Vasiliki Vartela, Dimitrios Tsiapras, Petros Sfirakis, Christos Kapelios, Stavros Dimopoulos, Loukas Kaklamanis, Dimitrios Ntegiannis, Theofani Antoniou, Themistokles Chamogeorgakis, Stamatis Adamopoulos

Background: In advanced heart failure patients, heart transplantation is currently the most effective treatment. However, in a low-organ environment, it is usually necessary to proceed in long-term mechanical circulatory support through left ventricular assist device (LVAD) implantation as bridge-to-transplantation METHODS: The study included all patients with advanced heart failure who underwent continuous flow LVAD implantation as a bridge to transplant strategy in our centre (n = 68). Following LVAD implantation and for the period that patients were on LVAD support, pump thrombosis, strokes, gastrointestinal bleeding and right heart failure occurrence rates were recorded. Outcomes were compared between patients implanted with HeartMate 3 (HM3) and HeartWare (hVAD) LVADs as well as between patients who did reach heart transplantation (HTx group) and those who did not (noHTx group).

Results: 35 out of 68 patients underwent heart transplantation at a mean time of 691 ± 457 days. 41 patients received a HeartWare hVAD and 27 a HeartMate 3 (HM3) device. HM3 patients had significantly better survival (p = 0.010) and lower complication rates (p = 0.025). Additionally, the noHTx group had significantly higher complication rates compared to the HTx group (p = 0.00041). The five-year estimated Kaplan-Meier survival rates following heart transplantation was 77%.

Conclusions: Patients with advanced heart failure gain substantial benefit from left ventricular assist devices awaiting heart transplantation. In a low organ donation environment, the need for reliable left ventricular assist devices can further improve the outcomes through the reduction of complications provided by current devices.

背景:对于晚期心力衰竭患者,心脏移植是目前最有效的治疗方法。然而,在低器官环境中,通常需要通过植入左心室辅助装置(LVAD)进行长期机械循环支持,作为移植前的过渡方法。研究记录了患者植入 LVAD 后和接受 LVAD 支持期间的泵血栓、中风、消化道出血和右心衰竭发生率。对植入 HeartMate 3 (HM3) 和 HeartWare (hVAD) LVAD 的患者以及接受心脏移植(HTx 组)和未接受心脏移植(noHTx 组)的患者的结果进行了比较:68名患者中有35名接受了心脏移植,平均时间为691±457天。41 名患者接受了 HeartWare hVAD 装置,27 名患者接受了 HeartMate 3 (HM3) 装置。HM3 患者的存活率明显更高(p = 0.010),并发症发生率更低(p = 0.025)。此外,与 HTx 组相比,无 HTx 组的并发症发生率明显更高(p = 0.00041)。心脏移植后的五年卡普兰-梅耶尔生存率估计为77%:结论:等待心脏移植的晚期心力衰竭患者可从左心室辅助装置中获益良多。结论:等待心脏移植的晚期心力衰竭患者从左心室辅助装置中获益良多。在器官捐赠较少的情况下,需要可靠的左心室辅助装置,通过减少现有装置带来的并发症,可进一步改善预后。
{"title":"Comparison of continuous flow centrifugal left ventricular assist devices as a bridge to transplant strategy in a low organ donation environment: Single center experience.","authors":"Michael Bonios, Dimitris Miliopoulos, Angeliki Gkouziouta, Nektarios Kogerakis, Sokratis Fragkoulis, Iakovos Armenis, Dimitrios Zarkalis, Konstantinos Ieromonachos, Antigoni Koliopoulou, Evangelos Leontiadis, Panagiota Georgiadou, Vasiliki Vartela, Dimitrios Tsiapras, Petros Sfirakis, Christos Kapelios, Stavros Dimopoulos, Loukas Kaklamanis, Dimitrios Ntegiannis, Theofani Antoniou, Themistokles Chamogeorgakis, Stamatis Adamopoulos","doi":"10.1016/j.hjc.2024.10.004","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.10.004","url":null,"abstract":"<p><strong>Background: </strong>In advanced heart failure patients, heart transplantation is currently the most effective treatment. However, in a low-organ environment, it is usually necessary to proceed in long-term mechanical circulatory support through left ventricular assist device (LVAD) implantation as bridge-to-transplantation METHODS: The study included all patients with advanced heart failure who underwent continuous flow LVAD implantation as a bridge to transplant strategy in our centre (n = 68). Following LVAD implantation and for the period that patients were on LVAD support, pump thrombosis, strokes, gastrointestinal bleeding and right heart failure occurrence rates were recorded. Outcomes were compared between patients implanted with HeartMate 3 (HM3) and HeartWare (hVAD) LVADs as well as between patients who did reach heart transplantation (HTx group) and those who did not (noHTx group).</p><p><strong>Results: </strong>35 out of 68 patients underwent heart transplantation at a mean time of 691 ± 457 days. 41 patients received a HeartWare hVAD and 27 a HeartMate 3 (HM3) device. HM3 patients had significantly better survival (p = 0.010) and lower complication rates (p = 0.025). Additionally, the noHTx group had significantly higher complication rates compared to the HTx group (p = 0.00041). The five-year estimated Kaplan-Meier survival rates following heart transplantation was 77%.</p><p><strong>Conclusions: </strong>Patients with advanced heart failure gain substantial benefit from left ventricular assist devices awaiting heart transplantation. In a low organ donation environment, the need for reliable left ventricular assist devices can further improve the outcomes through the reduction of complications provided by current devices.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of three-month treatment with pitavastatin on arterial stiffness in patients with hypercholesterolemia: a prospective observational study. 用匹伐他汀治疗三个月对高胆固醇血症患者动脉僵化的影响:一项前瞻性观察研究。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-18 DOI: 10.1016/j.hjc.2024.10.005
Hack-Lyoung Kim, Soonil Kwon, Hyun Sung Joh, Woo-Hyun Lim, Jae-Bin Seo, Sang-Hyun Kim, Joo-Hee Zo, Myung-A Kim

Background: Although several studies have highlighted the benefits of statins in improving arterial stiffness, there is limited research on whether pitavastatin, a more recently developed statin, has similar effects. This study aimed to investigate the impact of pitavastatin on arterial stiffness in patients with hypercholesterolemia.

Methods: This prospective study enrolled 115 patients with hypercholesterolemia (mean age 59 years; 22% female) who had not previously been treated with statins. Participants underwent lifestyle interventions followed by administration of pitavastatin (2 or 4 mg daily) if target low-density lipoprotein (LDL) cholesterol levels were not achieved. The primary outcome measured was the change in brachial-ankle pulse wave velocity (baPWV) from baseline after three months of treatment.

Results: Pitavastatin treatment significantly reduced LDL cholesterol by 41.1% (from 158 ± 28 to 93.0 ± 29.6 mg/dL; P < 0.001). Additionally, systolic blood pressure (SBP) decreased significantly from 130 ± 14 mmHg to 126 ± 14 mmHg (P < 0.001), representing a 2.9% reduction, and baPWV decreased significantly from 1,522 ± 325 to 1,407 ± 289 cm/s (P < 0.001), a 7.6% reduction. There was a significant correlation between changes in SBP and changes in baPWV (r = 0.565; P < 0.001). Even after adjusting for changes in SBP, the reduction in baPWV induced by pitavastatin remained statistically significant (P < 0.001).

Conclusions: A three-month treatment with pitavastatin effectively reduced arterial stiffness in patients with hypercholesterolemia, alongside significant improvements in lipid profiles and blood pressure reductions. These findings support the use of pitavastatin for managing key cardiovascular risk factors.

背景:尽管多项研究都强调了他汀类药物在改善动脉僵化方面的益处,但关于最近开发的他汀类药物匹伐他汀是否具有类似效果的研究却很有限。本研究旨在探讨匹伐他汀对高胆固醇血症患者动脉僵化的影响:这项前瞻性研究共招募了 115 名高胆固醇血症患者(平均年龄 59 岁;22% 为女性),他们之前未接受过他汀类药物治疗。参与者接受了生活方式干预,如果未达到目标低密度脂蛋白(LDL)胆固醇水平,则服用匹伐他汀(每天 2 或 4 毫克)。测量的主要结果是治疗三个月后肱踝脉搏波速度(baPWV)与基线相比的变化:结果:匹伐他汀治疗后,低密度脂蛋白胆固醇明显降低了 41.1%(从 158 ± 28 降至 93.0 ± 29.6 mg/dL;P < 0.001)。此外,收缩压 (SBP) 从 130 ± 14 mmHg 显著降至 126 ± 14 mmHg(P < 0.001),降幅为 2.9%;baPWV 从 1,522 ± 325 cm/s 显著降至 1,407 ± 289 cm/s (P < 0.001),降幅为 7.6%。SBP 的变化与 baPWV 的变化之间存在明显的相关性(r = 0.565;P < 0.001)。即使在调整了SBP的变化后,匹伐他汀引起的baPWV下降仍具有统计学意义(P < 0.001):结论:使用匹伐他汀进行为期三个月的治疗可有效降低高胆固醇血症患者的动脉僵化程度,同时显著改善血脂状况并降低血压。这些研究结果支持使用匹伐他汀来控制主要的心血管风险因素。
{"title":"Impact of three-month treatment with pitavastatin on arterial stiffness in patients with hypercholesterolemia: a prospective observational study.","authors":"Hack-Lyoung Kim, Soonil Kwon, Hyun Sung Joh, Woo-Hyun Lim, Jae-Bin Seo, Sang-Hyun Kim, Joo-Hee Zo, Myung-A Kim","doi":"10.1016/j.hjc.2024.10.005","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.10.005","url":null,"abstract":"<p><strong>Background: </strong>Although several studies have highlighted the benefits of statins in improving arterial stiffness, there is limited research on whether pitavastatin, a more recently developed statin, has similar effects. This study aimed to investigate the impact of pitavastatin on arterial stiffness in patients with hypercholesterolemia.</p><p><strong>Methods: </strong>This prospective study enrolled 115 patients with hypercholesterolemia (mean age 59 years; 22% female) who had not previously been treated with statins. Participants underwent lifestyle interventions followed by administration of pitavastatin (2 or 4 mg daily) if target low-density lipoprotein (LDL) cholesterol levels were not achieved. The primary outcome measured was the change in brachial-ankle pulse wave velocity (baPWV) from baseline after three months of treatment.</p><p><strong>Results: </strong>Pitavastatin treatment significantly reduced LDL cholesterol by 41.1% (from 158 ± 28 to 93.0 ± 29.6 mg/dL; P < 0.001). Additionally, systolic blood pressure (SBP) decreased significantly from 130 ± 14 mmHg to 126 ± 14 mmHg (P < 0.001), representing a 2.9% reduction, and baPWV decreased significantly from 1,522 ± 325 to 1,407 ± 289 cm/s (P < 0.001), a 7.6% reduction. There was a significant correlation between changes in SBP and changes in baPWV (r = 0.565; P < 0.001). Even after adjusting for changes in SBP, the reduction in baPWV induced by pitavastatin remained statistically significant (P < 0.001).</p><p><strong>Conclusions: </strong>A three-month treatment with pitavastatin effectively reduced arterial stiffness in patients with hypercholesterolemia, alongside significant improvements in lipid profiles and blood pressure reductions. These findings support the use of pitavastatin for managing key cardiovascular risk factors.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing the predictive ability of GRACE 2.0 and GRACE 3.0 scores in a Greek cohort of patients hospitalized with acute coronary syndrome.
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-14 DOI: 10.1016/j.hjc.2024.10.002
Christos Kofos, Andreas S Papazoglou, Stavroula Rousopoulou, Paraskevi Douki, Andreas Takas, Athanasios Samaras, Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, Barbara Fyntanidou, Nikolaos Fragakis, George Kassimis
{"title":"Comparing the predictive ability of GRACE 2.0 and GRACE 3.0 scores in a Greek cohort of patients hospitalized with acute coronary syndrome.","authors":"Christos Kofos, Andreas S Papazoglou, Stavroula Rousopoulou, Paraskevi Douki, Andreas Takas, Athanasios Samaras, Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, Barbara Fyntanidou, Nikolaos Fragakis, George Kassimis","doi":"10.1016/j.hjc.2024.10.002","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.10.002","url":null,"abstract":"","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New guidelines of EACTS/STS on aortic disease: A useful tool for the management of "aortic organ" disease. EACTS/STS 关于主动脉疾病的新指南:管理 "主动脉器官 "疾病的有用工具。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-09 DOI: 10.1016/j.hjc.2024.10.001
Nikolaos Schizas, Panagiotis Dedeilias
{"title":"New guidelines of EACTS/STS on aortic disease: A useful tool for the management of \"aortic organ\" disease.","authors":"Nikolaos Schizas, Panagiotis Dedeilias","doi":"10.1016/j.hjc.2024.10.001","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.10.001","url":null,"abstract":"","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142407217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ECMO versus IABP for STEMI Patients Complicated by Cardiogenic Shock undergoing Primary PCI: A Chinese National Study and Propensity-matched Analysis. 对接受初级 PCI 的 STEMI 并发心源性休克患者进行 ECMO 与 IABP 治疗:一项中国全国性研究和倾向匹配分析。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-07 DOI: 10.1016/j.hjc.2024.09.008
Hongbo Yang, Lingfeng Luo, Yanan Song, Jiatian Cao, Jing Chen, Feng Zhang, Yiwen Tan, Yan Zheng, Zhonghan Sun, Juying Qian, Zheyong Huang, Junbo Ge

Objectives: This study investigated the association between the utilization of extracorporeal membrane oxygenation (ECMO) or intra-aortic balloon pump (IABP) and in-hospital mortality among patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock undergoing primary percutaneous coronary intervention (PCI).

Methods: Data encompassing 9635 cases of STEMI complicated by cardiogenic shock and treated with primary PCI using ECMO/IABP support were retrieved from the Chinese Cardiovascular Association database (2019-2021). We conducted an analysis to assess in-hospital survival disparities among percutaneous mechanical circulatory device recipients and explore the potential advantages of ECMO through multivariable logistic regression analysis within a propensity score-matched (1:2) cohort population.

Results: ECMO was administered to 2028 patients, while IABP was utilized in 7607 patients. Patients supported by ECMO showed a lower in-hospital mortality compared with those supported by IABP (7.2% vs. 15.1%, p<0.001). Within the propensity-matched (case : control=1:2) cohort, we noted a 34% reduced risk of in-hospital mortality among patients supported by ECMO compared to those supported by IABP (7.7% vs. 11.7%; odds ratio = 0.66; 95% CI, 0.53-0.80; p< 0.001) independent of age, sex, systolic blood pressure, obesity, smoke, hypertension, diabetes, dyslipidaemia, family history of coronary artery disease, coronary artery disease, stroke, atrial filiation, peripheral artery disease, chronic kidney disease, vascular lesion sites, 3A-grade hospital, and regional distributions in China.

Conclusions: Among patients undergoing primary PCI for STEMI complicated by cardiogenic shock, ECMO was associated with better in-hospital survival than IABP.

研究目的本研究探讨了ST段抬高型心肌梗死(STEMI)并发心源性休克接受经皮冠状动脉介入治疗(PCI)的患者使用体外膜肺氧合(ECMO)或主动脉内球囊反搏泵(IABP)与院内死亡率之间的关系:从中华医学会心血管病学分会数据库(2019-2021年)中检索了9635例STEMI并发心源性休克、使用ECMO/IABP支持进行初级PCI治疗的患者数据。我们进行了一项分析,以评估经皮机械循环装置接受者的院内存活率差异,并在倾向评分匹配(1:2)队列人群中通过多变量逻辑回归分析探索 ECMO 的潜在优势:结果:2028 名患者使用了 ECMO,7607 名患者使用了 IABP。与使用 IABP 的患者相比,使用 ECMO 的患者院内死亡率较低(7.2% vs. 15.1%,pConclusions):在接受初级 PCI 治疗 STEMI 并发心源性休克的患者中,ECMO 的院内存活率高于 IABP。
{"title":"ECMO versus IABP for STEMI Patients Complicated by Cardiogenic Shock undergoing Primary PCI: A Chinese National Study and Propensity-matched Analysis.","authors":"Hongbo Yang, Lingfeng Luo, Yanan Song, Jiatian Cao, Jing Chen, Feng Zhang, Yiwen Tan, Yan Zheng, Zhonghan Sun, Juying Qian, Zheyong Huang, Junbo Ge","doi":"10.1016/j.hjc.2024.09.008","DOIUrl":"https://doi.org/10.1016/j.hjc.2024.09.008","url":null,"abstract":"<p><strong>Objectives: </strong>This study investigated the association between the utilization of extracorporeal membrane oxygenation (ECMO) or intra-aortic balloon pump (IABP) and in-hospital mortality among patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock undergoing primary percutaneous coronary intervention (PCI).</p><p><strong>Methods: </strong>Data encompassing 9635 cases of STEMI complicated by cardiogenic shock and treated with primary PCI using ECMO/IABP support were retrieved from the Chinese Cardiovascular Association database (2019-2021). We conducted an analysis to assess in-hospital survival disparities among percutaneous mechanical circulatory device recipients and explore the potential advantages of ECMO through multivariable logistic regression analysis within a propensity score-matched (1:2) cohort population.</p><p><strong>Results: </strong>ECMO was administered to 2028 patients, while IABP was utilized in 7607 patients. Patients supported by ECMO showed a lower in-hospital mortality compared with those supported by IABP (7.2% vs. 15.1%, p<0.001). Within the propensity-matched (case : control=1:2) cohort, we noted a 34% reduced risk of in-hospital mortality among patients supported by ECMO compared to those supported by IABP (7.7% vs. 11.7%; odds ratio = 0.66; 95% CI, 0.53-0.80; p< 0.001) independent of age, sex, systolic blood pressure, obesity, smoke, hypertension, diabetes, dyslipidaemia, family history of coronary artery disease, coronary artery disease, stroke, atrial filiation, peripheral artery disease, chronic kidney disease, vascular lesion sites, 3A-grade hospital, and regional distributions in China.</p><p><strong>Conclusions: </strong>Among patients undergoing primary PCI for STEMI complicated by cardiogenic shock, ECMO was associated with better in-hospital survival than IABP.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Central versus peripheral VA ECMO for cardiogenic shock: an 8-year experience of a tertiary cardiac surgery center in Greece. 中心与外周 VA ECMO 治疗心源性休克:希腊一家三级心脏外科中心 8 年的经验。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-30 DOI: 10.1016/j.hjc.2024.09.006
Michael Antonopoulos, Antigone Koliopoulou, Dimitrios Elaiopoulos, Kyriaki Kolovou, Dimitra Doubou, Anna Smyrli, Prodromos Zavaropoulos, Nektarios Kogerakis, Sokratis Fragoulis, Konstantinos Perreas, Georgios Stavridis, Stamatis Adamopoulos, Themistocles Chamogeorgakis, Stavros Dimopoulos

Background: VA ECMO has emerged as an effective rescue therapy in patients with cardiogenic shock refractory to standard treatment protocols and its use is rising worldwide in the last decade. Although experience and availability are growing, outcomes remain poor. There is need for evidence to ameliorate clinical practice and improve outcomes.

Methods: We retrospectively reviewed the medical records of all patients who were supported with VA ECMO for cardiogenic shock at our institution between January 2015 and January 2023. The study purpose was to compare outcomes between patients who were supported with central versus peripheral configuration.

Results: ECMO was applied in 108 patients of whom central configuration in 48 (44%) and peripheral in 60 (56%). Patients supported with central VA ECMO were more likely to be supported for post cardiotomy shock [OR 4.6 (CI 95% 2.03 - 10.41)], while patients in the peripheral group for chronic heart failure decompensation [OR 9.4 (CI 95% 1.16 - 76.3]. Central VA ECMO had worse survival during ECMO support (29.2% vs 51.7%, p=0.018) and at discharge (8% vs 37%, p=0.001). These patients were at high risk of complications, such as acute kidney injury (AKI), [OR 2.37 (CI 95% 1.06 - 5.3), p = 0.034] and major bleeding [OR 3.08 (CI 95% 1.36 - 6.94), p<0.001].

Conclusions: Patients on central VA ECMO were supported mainly for post cardiotomy shock, presented with more complications such as major bleeding and AKI and had worse survival to hospital discharge, compared with patients on peripheral VA ECMO. Patient selection, timing of implementation, cannulation strategy and configuration remain main determinants of clinical outcome.

背景:VA ECMO 已成为标准治疗方案难治性心源性休克患者的一种有效抢救疗法,近十年来其使用率在全球范围内不断上升。尽管经验和可用性在不断增加,但疗效仍然不佳。我们需要证据来改善临床实践并提高疗效:我们回顾性地查看了 2015 年 1 月至 2023 年 1 月期间在本院接受 VA ECMO 治疗的所有心源性休克患者的病历。研究目的是比较中心配置与外周配置患者的治疗效果:108 名患者使用了 ECMO,其中 48 人(44%)使用中心配置,60 人(56%)使用外周配置。中央 VA ECMO 支持的患者更有可能因心脏切除术后休克而接受支持[OR 4.6 (CI 95% 2.03 - 10.41)],而外周组患者则因慢性心衰失代偿而接受支持[OR 9.4 (CI 95% 1.16 - 76.3]。中心 VA ECMO 在 ECMO 支持期间(29.2% 对 51.7%,P=0.018)和出院时(8% 对 37%,P=0.001)的存活率较低。这些患者出现并发症的风险很高,如急性肾损伤(AKI)[OR 2.37 (CI 95% 1.06 - 5.3), p = 0.034]和大出血[OR 3.08 (CI 95% 1.36 - 6.94), p结论:与使用外周 VA ECMO 的患者相比,使用中心 VA ECMO 的患者主要用于治疗心脏切除术后休克,并发症(如大出血和 AKI)较多,出院后存活率较低。患者选择、实施时机、插管策略和配置仍是临床结果的主要决定因素。
{"title":"Central versus peripheral VA ECMO for cardiogenic shock: an 8-year experience of a tertiary cardiac surgery center in Greece.","authors":"Michael Antonopoulos, Antigone Koliopoulou, Dimitrios Elaiopoulos, Kyriaki Kolovou, Dimitra Doubou, Anna Smyrli, Prodromos Zavaropoulos, Nektarios Kogerakis, Sokratis Fragoulis, Konstantinos Perreas, Georgios Stavridis, Stamatis Adamopoulos, Themistocles Chamogeorgakis, Stavros Dimopoulos","doi":"10.1016/j.hjc.2024.09.006","DOIUrl":"10.1016/j.hjc.2024.09.006","url":null,"abstract":"<p><strong>Background: </strong>VA ECMO has emerged as an effective rescue therapy in patients with cardiogenic shock refractory to standard treatment protocols and its use is rising worldwide in the last decade. Although experience and availability are growing, outcomes remain poor. There is need for evidence to ameliorate clinical practice and improve outcomes.</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of all patients who were supported with VA ECMO for cardiogenic shock at our institution between January 2015 and January 2023. The study purpose was to compare outcomes between patients who were supported with central versus peripheral configuration.</p><p><strong>Results: </strong>ECMO was applied in 108 patients of whom central configuration in 48 (44%) and peripheral in 60 (56%). Patients supported with central VA ECMO were more likely to be supported for post cardiotomy shock [OR 4.6 (CI 95% 2.03 - 10.41)], while patients in the peripheral group for chronic heart failure decompensation [OR 9.4 (CI 95% 1.16 - 76.3]. Central VA ECMO had worse survival during ECMO support (29.2% vs 51.7%, p=0.018) and at discharge (8% vs 37%, p=0.001). These patients were at high risk of complications, such as acute kidney injury (AKI), [OR 2.37 (CI 95% 1.06 - 5.3), p = 0.034] and major bleeding [OR 3.08 (CI 95% 1.36 - 6.94), p<0.001].</p><p><strong>Conclusions: </strong>Patients on central VA ECMO were supported mainly for post cardiotomy shock, presented with more complications such as major bleeding and AKI and had worse survival to hospital discharge, compared with patients on peripheral VA ECMO. Patient selection, timing of implementation, cannulation strategy and configuration remain main determinants of clinical outcome.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of bystander CPR in out-of-hospital cardiac arrest: what the evidence tells us. 旁观者 CPR 在院外心脏骤停中的作用:证据告诉我们什么?
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-12 DOI: 10.1016/j.hjc.2024.09.002
Natália C Oliveira, Hugo Oliveira, Thamires L C Silva, Maria Boné, Jorge Bonito

Out-of-hospital cardiac arrest (OHCA) is a global public health problem. Lay bystanders witness almost half of OHCA, so early recognition is critical to allow immediate initiation of cardiopulmonary resuscitation (CPR) by the bystander. The present investigation aims to analyze the most recent scientific evidence of the effect of bystander CPR on survival after an OHCA. A systematic literature review was carried out at the "Web of Science," "Scopus," and "PubMed" databases, including publications from the last 20 years. After inclusion/exclusion criteria, 37 articles were identified. Results indicate that patients who receive CPR are more likely to survive than those who don't, and CPR is associated with a good quality of life post-OHCA. Emphasis should be placed on practicing chest compressions only when the bystander has not mastered the artificial ventilation technique. Finding an AED is the first step to using it in an OHCA situation. Correct use of an AED by laypeople is associated with nearly double the survival rate after an OHCA when compared to standard CPR. It is important to promote CPR and AED training to non-professionals, such as community residents and youth, as training is associated with higher success rates of effective CPR-AED. A mobile phone positioning system to recruit trained laypeople or text message alerts to send citizen volunteers as well as assistance through a mobile app appear to have significant advantages in practicing effective CPR. The benefits of bystander CPR outweigh the risk of injury to victims, highlighting the need to disseminate training to laypeople.

院外心脏骤停(OHCA)是一个全球性的公共卫生问题。旁观者目睹了近一半的院外心脏骤停,因此早期识别对于旁观者立即启动心肺复苏(CPR)至关重要。本调查旨在分析旁观者心肺复苏术对 OHCA 后存活率影响的最新科学证据。我们在 "Web of Science"、"Scopus "和 "PubMed "数据库中进行了系统的文献综述,包括过去 20 年的出版物。根据纳入/排除标准,共确定了 37 篇文章。结果表明,接受心肺复苏术的患者比未接受心肺复苏术的患者更有可能存活,而且心肺复苏术与 OHCA 后良好的生活质量有关。只有当旁观者尚未掌握人工通气技术时,才应强调练习胸外按压。找到自动体外除颤器是在 OHCA 情况下使用它的第一步。与标准心肺复苏术相比,普通人正确使用自动体外除颤器可使 OHCA 后的存活率提高近一倍。向社区居民和青少年等非专业人员推广心肺复苏术和自动体外除颤器培训非常重要,因为培训与更高的有效心肺复苏术-自动体外除颤器成功率相关。招募训练有素的非专业人员的手机定位系统或发送公民志愿者的短信提醒,以及通过手机应用程序提供的帮助,似乎在实施有效的心肺复苏术方面具有显著优势。旁观者心肺复苏术的益处超过了对受害者造成伤害的风险,这凸显了向非专业人员提供培训的必要性。
{"title":"The role of bystander CPR in out-of-hospital cardiac arrest: what the evidence tells us.","authors":"Natália C Oliveira, Hugo Oliveira, Thamires L C Silva, Maria Boné, Jorge Bonito","doi":"10.1016/j.hjc.2024.09.002","DOIUrl":"10.1016/j.hjc.2024.09.002","url":null,"abstract":"<p><p>Out-of-hospital cardiac arrest (OHCA) is a global public health problem. Lay bystanders witness almost half of OHCA, so early recognition is critical to allow immediate initiation of cardiopulmonary resuscitation (CPR) by the bystander. The present investigation aims to analyze the most recent scientific evidence of the effect of bystander CPR on survival after an OHCA. A systematic literature review was carried out at the \"Web of Science,\" \"Scopus,\" and \"PubMed\" databases, including publications from the last 20 years. After inclusion/exclusion criteria, 37 articles were identified. Results indicate that patients who receive CPR are more likely to survive than those who don't, and CPR is associated with a good quality of life post-OHCA. Emphasis should be placed on practicing chest compressions only when the bystander has not mastered the artificial ventilation technique. Finding an AED is the first step to using it in an OHCA situation. Correct use of an AED by laypeople is associated with nearly double the survival rate after an OHCA when compared to standard CPR. It is important to promote CPR and AED training to non-professionals, such as community residents and youth, as training is associated with higher success rates of effective CPR-AED. A mobile phone positioning system to recruit trained laypeople or text message alerts to send citizen volunteers as well as assistance through a mobile app appear to have significant advantages in practicing effective CPR. The benefits of bystander CPR outweigh the risk of injury to victims, highlighting the need to disseminate training to laypeople.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of neutrophil extracellular traps burden with clinical and angiographic characteristics in patients with ST-elevation myocardial infarction. ST段抬高型心肌梗死患者的中性粒细胞胞外捕获物负担与临床和血管造影特征的关系
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-07 DOI: 10.1016/j.hjc.2024.09.001
Nikolaos Stalikas, Sofia-Eleni Tzorakoleftheraki, Efstratios Karagiannidis, Matthaios Didagelos, Antonios Ziakas, Vasileios Kamperidis, George Giannakoulas, Vasileios Vassilikos, Triantafyllia Koletsa, George Giannopoulos

Background: The precise triggers for atherosclerotic plaque rupture and the underlying pathophysiology of coronary thrombogenesis remain elusive. Polymorphonuclear neutrophils, particularly their formation of neutrophil extracellular traps (NETs), have garnered attention in the context of coronary atherothrombosis. This study sought to explore the association of NETs burden with clinical and angiographic characteristics in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (pPCI) and thrombus aspiration (TA).

Methods: For this study, 336 consecutive STEMI patients undergoing pPCI were considered for TA. Aspirated thrombi underwent histological analysis and NETs quantification via immunohistochemistry. Potential associations of clinical variables and angiographic outcomes with NETs burden were assessed.

Results: Manual TA was selectively performed in 72 cases with increased thrombotic burden, and 60 thrombi were suitable for analysis and included in the current study. Most thrombi specimens displayed lytic features (63%), and almost three out of four were identified as white thrombi. Increased NETs burden was significantly associated with prolonged pain-to-balloon time (>300 min), OR = 10.29 (95% CI 2.11-42.22, p = 0.001), and stress-induced hyperglycemia OR = 6.58 (95% CI 1.23-52.63, p < 0.01) after multivariate regression analysis. Additionally, distal embolization, and left ventricular ejection fraction ≤40% were more frequent among patients with an elevated NETs burden OR = 16.9 (95% CI 4.23-44.52, p < 0.01) and OR = 3.2 (95% CI 1.05-12.1, p = 0.05), respectively.

Conclusion: Elevated NETs burden in STEMI thrombi may be due to delayed reperfusion and stress-induced hyperglycemia, and it is associated with an increased risk of distal embolization and lower left ventricular ejection fraction. Further research is needed to elucidate the role of NETs as a potential therapeutic target in acute atherothrombosis.

背景:动脉粥样硬化斑块破裂的确切诱因和冠状动脉血栓形成的潜在病理生理学仍然难以捉摸。多形核中性粒细胞,尤其是它们形成的中性粒细胞胞外陷阱(NETs),在冠状动脉粥样硬化血栓形成中引起了关注。本研究旨在探讨接受经皮冠状动脉介入治疗(pPCI)和血栓抽吸术(TA)的ST段抬高型心肌梗死(STEMI)患者的NETs负担与临床和血管造影特征之间的关系:在这项研究中,考虑对 336 名连续接受经皮冠状动脉介入治疗的 STEMI 患者进行血栓抽吸。抽吸出的血栓进行了组织学分析,并通过免疫组化对NETs进行了定量。评估了临床变量和血管造影结果与 NETs 负荷的潜在关联:对72例血栓负担加重的病例选择性地进行了人工TA,有60个血栓适合进行分析并纳入本次研究。大多数血栓标本具有溶解特征(63%),几乎四分之三的标本被鉴定为白色血栓。NETs负荷增加与疼痛至气球时间延长(>300分钟)(OR=10.29 (95% CI 2.11-42.22, p=0.001))和应激性高血糖(OR=6.58 (95% CI 1.23-52.63, p)明显相关:STEMI 血栓中 NETs 负荷升高可能是由于再灌注延迟、应激诱发的高血糖所致,并且与远端栓塞风险增加有关。需要进一步研究以阐明 NETs 在急性动脉粥样硬化血栓形成中作为潜在治疗靶点的作用。
{"title":"Association of neutrophil extracellular traps burden with clinical and angiographic characteristics in patients with ST-elevation myocardial infarction.","authors":"Nikolaos Stalikas, Sofia-Eleni Tzorakoleftheraki, Efstratios Karagiannidis, Matthaios Didagelos, Antonios Ziakas, Vasileios Kamperidis, George Giannakoulas, Vasileios Vassilikos, Triantafyllia Koletsa, George Giannopoulos","doi":"10.1016/j.hjc.2024.09.001","DOIUrl":"10.1016/j.hjc.2024.09.001","url":null,"abstract":"<p><strong>Background: </strong>The precise triggers for atherosclerotic plaque rupture and the underlying pathophysiology of coronary thrombogenesis remain elusive. Polymorphonuclear neutrophils, particularly their formation of neutrophil extracellular traps (NETs), have garnered attention in the context of coronary atherothrombosis. This study sought to explore the association of NETs burden with clinical and angiographic characteristics in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (pPCI) and thrombus aspiration (TA).</p><p><strong>Methods: </strong>For this study, 336 consecutive STEMI patients undergoing pPCI were considered for TA. Aspirated thrombi underwent histological analysis and NETs quantification via immunohistochemistry. Potential associations of clinical variables and angiographic outcomes with NETs burden were assessed.</p><p><strong>Results: </strong>Manual TA was selectively performed in 72 cases with increased thrombotic burden, and 60 thrombi were suitable for analysis and included in the current study. Most thrombi specimens displayed lytic features (63%), and almost three out of four were identified as white thrombi. Increased NETs burden was significantly associated with prolonged pain-to-balloon time (>300 min), OR = 10.29 (95% CI 2.11-42.22, p = 0.001), and stress-induced hyperglycemia OR = 6.58 (95% CI 1.23-52.63, p < 0.01) after multivariate regression analysis. Additionally, distal embolization, and left ventricular ejection fraction ≤40% were more frequent among patients with an elevated NETs burden OR = 16.9 (95% CI 4.23-44.52, p < 0.01) and OR = 3.2 (95% CI 1.05-12.1, p = 0.05), respectively.</p><p><strong>Conclusion: </strong>Elevated NETs burden in STEMI thrombi may be due to delayed reperfusion and stress-induced hyperglycemia, and it is associated with an increased risk of distal embolization and lower left ventricular ejection fraction. Further research is needed to elucidate the role of NETs as a potential therapeutic target in acute atherothrombosis.</p>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronary artery thromboembolism as a cause of myocardial infarction with non-obstructive coronary arteries (MINOCA) 冠状动脉血栓栓塞是冠状动脉非阻塞性心肌梗死(MINOCA)的病因之一。
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 DOI: 10.1016/j.hjc.2024.05.001

Acute myocardial infarction (AMI) usually represents the clinical manifestation of atherothrombotic coronary artery disease (CAD) resulting from atherosclerotic plaque rupture. However, there are cases in which coronary angiography or coronary computed tomography angiography reveals patients with acute coronary syndrome with non-obstructive CAD. This clinical entity is defined as myocardial infarction with non-obstructive coronary arteries (MINOCA) and often considered as a clinical dynamic working diagnosis that needs further investigations for the establishment of a final etiologic diagnosis. The main causes of a MINOCA working diagnosis include atherosclerotic, non-atherosclerotic (vessel-related and non–vessel-related), and thromboembolic causes This literature review aimed to investigate the major thromboembolic causes in patients presenting with MINOCA regarding their etiology and pathophysiologic mechanisms, as well as diagnostic and treatment methods.

急性心肌梗死(AMI)通常是动脉粥样硬化斑块破裂导致的粥样血栓性冠状动脉疾病(CAD)的临床表现。然而,在某些情况下,冠状动脉造影术或冠状动脉计算机断层扫描血管造影术会发现急性冠状动脉综合征患者伴有非阻塞性 CAD。这种临床实体被定义为冠状动脉非阻塞性心肌梗死(MINOCA),通常被认为是一种临床动态工作诊断,需要进一步检查才能确定最终的病因诊断。导致 MINOCA 工作诊断的主要原因包括动脉粥样硬化、非动脉粥样硬化(血管相关和非血管相关)和血栓栓塞原因。本文献综述旨在从病因学、病理生理学机制以及诊断和治疗方法等方面研究 MINOCA 患者的主要血栓栓塞原因。
{"title":"Coronary artery thromboembolism as a cause of myocardial infarction with non-obstructive coronary arteries (MINOCA)","authors":"","doi":"10.1016/j.hjc.2024.05.001","DOIUrl":"10.1016/j.hjc.2024.05.001","url":null,"abstract":"<div><p>Acute myocardial infarction (AMI) usually represents the clinical manifestation of atherothrombotic coronary artery disease (CAD) resulting from atherosclerotic plaque rupture. However, there are cases in which coronary angiography or coronary computed tomography angiography reveals patients with acute coronary syndrome with non-obstructive CAD. This clinical entity is defined as myocardial infarction with non-obstructive coronary arteries (MINOCA) and often considered as a clinical dynamic working diagnosis that needs further investigations for the establishment of a final etiologic diagnosis. The main causes of a MINOCA working diagnosis include atherosclerotic, non-atherosclerotic (vessel-related and non–vessel-related), and thromboembolic causes This literature review aimed to investigate the major thromboembolic causes in patients presenting with MINOCA regarding their etiology and pathophysiologic mechanisms, as well as diagnostic and treatment methods.</p></div>","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1109966624001052/pdfft?md5=c3dfca621877bbdb369e93d24ecb20cb&pid=1-s2.0-S1109966624001052-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141201553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiogenetics: que será, será. Ou non? 心脏遗传学:是,是。还是不?
IF 2.7 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 DOI: 10.1016/j.hjc.2024.09.003
{"title":"Cardiogenetics: que será, será. Ou non?","authors":"","doi":"10.1016/j.hjc.2024.09.003","DOIUrl":"10.1016/j.hjc.2024.09.003","url":null,"abstract":"","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1109966624002021/pdfft?md5=142af1e8337503305ac179da08972198&pid=1-s2.0-S1109966624002021-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142243173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hellenic Journal of Cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1